Cary,
Speaking of relative value, did you know that back in early 1996 when this stock was selling for around $7.00/share and AccuMed had much less to offer Peter Gombrich made the following statement:
Number one, the company is very under-valued at this time, because it merged with a public shell, so it has a very low baseline. Number two, we are playing in a major market area that is nearly $3 billion untapped. And, three, we have a demonstrable product that is being sold and that has been tested by major laboratories who have expressed tremendous interest. (Wall Street Corporate Reporter, Vol.1, Issue 1 April 29-May5, 1996.)
Cisco |
